SLAMF7

Across TCGA pan-cancer cohorts, SLAMF7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLAMF7 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SLAMF7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLAMF7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, SCLC, and LAML are the cancer types where SLAMF7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.415	0.926	<.001	36	view →
SCLC	OS	Median	II,III,IV	0.082	0.648	<.001	24	view →
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
LGG	OS	Median	All	0.187	0.909	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.438	.018	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLAMF7–BRCA (OS)

Open the BRCA breakdown →